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Abstract
Background: The recurrence of gastric cancer after curative resection had adverse effects on patients’ survival. The
treatment presence varied from different countries. The aims of this study were to understand the recurrence
incidence, patterns, and timing and to explore the risk factors in China.
Methods: One thousand three hundred four patients who undergoing curative resection from more than 100
hospitals between January 1st 1986 and September 1st 2013, were surveyed in detail. Clinical pathological factors
were examined as potential risk factors of each recurrence pattern using univariate and multivariate analyses.
Recurrence timing was also analyzed based on disease-free survival.
Results: Among 1304 gastric cancer patients, 793 patients (60.8%) experienced recurrence and 554 patients
(42.5%) experienced recurrence within 2 years after operation. The median disease-free survival was 29.00 months
(interquartile range [IQR] 12.07, 147.23). Receiving operation in general hospitals was one of independent risk
factors of local-regional recurrence (OR = 1.724, 95% CI 1.312 to 2.265) and distant metastasis (OR = 1.496, 95% CI 1.
164 to 1.940). Patients would suffer lower risk of distant metastasis if they received no more than 3 cycles adjuvant
chemotherapy (OR = 0.640, 95% CI 0.433 to 0.943). Adjuvant radiotherapy could reduce the risk of recurrence (OR 0.
259, 95% CI 0.100 to 0.670), especially distant metastasis (OR = 0.260, 95% CI 0.083 to 0.816).
Conclusions: More than 60% patients experienced recurrence after curative resection for gastric cancer, especially
within 2 years after surgery. Risk factors were clarified between various recurrence patterns. Advanced gastric cancer
and undergoing operation in general hospitals contributed to increased recurrence risk and worse survival. Enough
number of lymph nodes harvest and standard D2 lymphadenectomy could reduce recurrence. Chinese patients
would benefit from adjuvant chemotherapy and radiotherapy.
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Background
Gastric cancer is the fourth common malignant tumor
in the world, and China is one of countries with high
gastric cancer incidence [1, 2]. So far, curative resection
has been considered as the only way to cure gastric
cancer. Recurrence after curative resection contributes
to the limited survival of patients. Recurrence patterns
generally include local-regional recurrence, distant or
hematogenous metastasis, and peritoneum implanting.
Recurrence patterns have related to adjuvant treatment
modes. For example, in America, local-regional recur-
rence and hematogenous metastasis were fairly common,
and patients could benefit from adjuvant radio-
chemotherapy [3–5]. While, in Japan and South Korea,
where distant metastasis and peritoneum implanting
were regular, patients could benefit from adjuvant
chemotherapy, rather than adjuvant radio-chemotherapy
[6–9]. Moreover, recurrence timing could provide infor-
mation of postoperative follow-up, in order to find
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recurrence timely. In China, several small sample single-
center studies had reported the recurrence patterns and
relative risk factors [10–12], but little large sample and
multiple centers analysis had reported recurrence timing
and survival. And the level of gastric cancer treatment
varied from different hospitals, sites, and times. So, that
exploring the actual recurrence patterns and timing was
necessary. It was the first large sample of multiple-
center retrospective analysis for recurrence patterns and
timing after curative gastric cancer resection in China.
We specifically analyzed the relationship between surgi-
cal hospitals and recurrence. It would provide more
information for clinicians in choosing individual treat-
ment schedules and predicting prognosis.
Methods
Patients
There were 1646 patients, who underwent operation for
gastric malignant tumors between January 1st 1986 and
September 1st 2013, in more than 100 Chinese hospitals,
screened for this analysis. All of them finally received
postoperative treatment in Gastrointestinal Tumor
Department of Beijing Cancer Hospital and Radiother-
apy Department of Fudan University Shanghai Cancer
Center. Three hundred forty-two patients were excluded
for the following reasons: (1) 192 patients underwent
palliative tumor resection (including both primary and
non-local regional metastasis lesions totally resected) or
experienced microscopically/visible positive (R1/R2)
margin status, (2) 67 patients whose postoperative histo-
logical examinations turned out not to be gastric adeno-
carcinoma, and (3) 83 patients experienced death whose
recurrence time and patterns were unclear. Finally, 1304
gastric adenocarcinoma patients were included in this
study for recurrence patterns and timing after curative
resection (Fig. 1).
Data collection
All patients’ clinical pathological characteristics, including
age, sex, tumor location, surgical hospitals (general and spe-
cialist hospitals), depth of tumor invasion, number of posi-
tive lymph nodes, extent of lymphadenectomy, histological
type, neo-adjuvant treatment, adjuvant treatment, and
recurrence and survival information were retrospectively
reviewed based on operative notes and medical records.
Pathological identification
Cardia and fundus tumors were identified as gastroesopha-
geal junction (GEJ) adenocarcinoma. Tumors located in
the rest sites of gastric were identified as non-
gastroesophageal junction (non-GEJ) adenocarcinoma. The
lymphadenectomy extent was defined according to the
2010 Japanese gastric cancer treatment guidelines [13].
The tumors’ stages were classified based on the postopera-
tive tissues, according to the 7th edition American Joint
Committee on Cancer (AJCC) staging system of gastric
adenocarcinoma. Histological classification was in ac-
cordance with the World Health Organization
(WHO) classification of tumors of the digestive sys-
tem [14]. Well-differentiated tumors included highly
and moderately differentiated papillary carcinoma.
And poorly differentiated included low differentiated
papillary carcinoma, mucinous adenocarcinoma, and
hepatoid adenocarcinoma. Recurrence was defined as
biopsy and imaging highly suspicious of recurrence.
Recurrence patterns included local-regional recurrence
(gastric or nodal), distant metastasis (organs and dis-
tant lymph nodes), and peritoneum implanting (peri-
toneum nodules, ascites, and Krukenberg tumors).
Postoperative follow-up
All patients were followed from the date of surgery to
death or emigration. The last follow-up of all recurrence
Fig. 1 The screening progress for analysis patients
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and survival information was January 7th 2015. Recur-
rence and survival data were obtained from patients’
medical records and telephone follow-up.
The recurrence free survival (RFS) was defined as the
time from surgery to recurrence or death of any other
causes. The overall survival (OS) was defined as the time
from operation to death. The recurrence occurred within
2 years after surgery was defined as early recurrence.
Recurrence patterns were classified based on the site of
the first recurrence. The recurrence inspected within
3 months after the first recurrence was regarded as
synchronous recurrence.
Table 1 The clinical pathological characteristics of patents
Clinical features No. of patients (n = 1304)
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Statistical analysis
Fifteen clinical relative characteristics were examined as
potential risk factors of recurrence. Differences between
two groups were assessed by the chi-square or Fisher
exact tests. The association of clinical pathological factors
with the extent of recurrence was assessed using logistic
models. Back-Wald method of multivariate analysis model
was used to avoid possible interaction factors for recur-
rence patterns. Survival curves were analyzed by Kaplan-
Meier method and compared by the log-rank test. All
analyses were carried out by SPSS version 22.0. The prog-
nostic powers of covariates were recorded by odds ratios
(ORs) and 95% confidence internals (CIs). All p values
<0.05 were considered statistically significant.
Results
Clinical pathological characteristics
Among the 1304 analyzed patients, the median age was
58.0 years old (IQR 48.0, 65.0). There were 981 males
(75.2%) and 323 females (24.8%), with a male-to-female
ratio of nearly 3:1. The most general tumor location was
the antrum (n = 437, 33.5%) and cardiac (n = 387, 29.7%).
Most patients (n = 1106, 84.8%) underwent subtotal gas-
trectomy. The median number of total lymph nodes dis-
section was 16 (IQR 10.24). And 697 (53.5%) patients
had lymph nodes dissection no less than 15. Patients
had more lymph nodes harvest in specialist hospitals
than in general hospitals (median number of lymph
nodes harvest 19 [IQR 13.27] vs. 13 [IQR 8.22]). And
the specialist hospitals had higher D2 lymphadenectomy
rate than general hospitals (63.0 vs. 39.0%, p < 0.001).
The median number of positive lymph nodes harvest
was 3 (IQR 0.7). A majority of patients (n = 1195, 91.6%)
suffered advanced gastric cancer. Only 63 patients
(4.8%) experienced neo-adjuvant chemotherapy, and no-
body received neo-adjuvant radiotherapy. A large subset
of patients (n = 1020, 78.2%) received adjuvant chemo-
therapy. Nine hundred seventy patients (74.4%) received
fluorouracil-based chemotherapy, and 44 patients (3.4%)
received other non-fluorouracil-based chemotherapy. Al-
most half of patients (n = 647, 49.6%) received adjuvant
chemotherapy over 3 cycles. Only 26 patients (2.0%) had
adjuvant radiotherapy (Table 1).
Recurrence patterns and recurrence-related risk factors
Patterns of recurrence and risk factors associated with
postoperative recurrence
The median follow-up was 56.58 months (IQR 30.45,
105.40), and 116 patients (8.7%) were lost during the
follow-up. Seven hundred ninety-three patients (60.8%)
suffered recurrence. And there were 423 patients
(32.4%) with local-regional recurrence, 575 patients
(44.3%) with distant metastasis, and 179 patients (13.7%)
suffering peritoneum implanting (Fig. 2). Four hundred
fifty-seven patients (57.5%) experienced single pattern
recurrence, while 336 patients (42.5%) experienced
multiple pattern recurrence. The distant lymph node
metastasis was more general than distant organ me-
tastasis (n = 392, 49.4 vs. n = 294, 37.0%). The general
organs of distant metastasis included liver (n = 154),
lung (n = 40), bone (n = 38), pleura (n = 25), and sub-
cutaneous nodule metastasis (n = 23).
Based on this database, several clinical pathological
factors were independent risk factors of recurrence in
any site (Table 2). Specially, patients who underwent
radical surgery in general hospitals (OR 1.632, 95% CI
1.238 to 2.151) and suffered signet ring cell cancer (OR
1.881, 95% CI 1.108 to 3.193) were more likely to experi-
ence recurrence. Patients receiving adjuvant radiother-
apy (OR 0.259, 95% CI 0.100 to 0.670) contributed to
lower recurrence risk.
Risk factors of each recurrence pattern
In exploring risk factors of recurrence patterns, different
clinical pathological factors contributed to specific recur-
rence patterns (Table 3). Receiving operation general
hospitals independently risk factors of local-regional
recurrence (OR = 1.724, 95% CI 1.312 to 2.265) and
distant metastasis (OR = 1.496, 95% CI 1.164 to 1.940).
D0/D1 lymphadenectomy increased the risk of local-
regional recurrence (OR = 2.272, 95% CI 1.734 to 2.977)
and distant metastasis (OR = 1.777, 95% CI 1.369 to
2.307). Patients >65 years increased the risk of distant
metastasis (OR 1.449, 95% CI 1.093 to 1.922), but
reduced the risk of peritoneum implanting (OR 0.619,
95% CI 0.403 to 0.984). Patients with factors, including
female (OR 1.687, 95% CI 1.164 to 2.444), signet ring
cell cancer (OR 2.627, 95% CI 1.449 to 4.761) were at
Fig. 2 The recurrence patterns of patients with curative gastrectomy
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Table 2 The univariate and multivariate analysis of postoperative recurrence
Clinical features Univariate analysis Multivariate analysis
OR 95% CI p value OR 95% CI p value
Age
≦65
>65 1.178 0.916–1.514 0.201 NA NA NA
Sex
Male
Female 0.837 0.648–1.080 0.171 NA NA NA
Hospital
Specialist hospitals
General hospitals 1.915 1.529–2.398 <0.001 1.632 1.238–2.151 0.001
Tumor location
Non-GEJ
GEJ 1.683 1.319–2.146 <0.001 1.431 1.066–1.922 0.017
AJCC stage
I–II
III 2.608 2.070–3.286 <0.001 NA NA NA
T stage
T1–2
T3–4 2.861 2.188–3.741 <0.001 2.332 1.675–3.245 <0.001
N stage
N0
N1–3 3.397 2.617–4.409 <0.001 2.085 1.481–2.936 <0.001
Positive LN ratio
≦0.33
>0.33 3.577 2.759–4.638 <0.001 2.283 1.656–3.145 <0.001
No. of LN dissection
<15
≧15 0.502 0.397–0.635 <0.001 NA NA NA
Histological type
Well-differentiated tumors
Poorly differentiated tumors 0.845 0.645–1.107 0.222 0.792 0.570–1.099 0.162
Signet ring cell cancer 2.066 1.307–3.265 0.002 1.881 1.108–3.193 0.019
Lymphadenectomy extent
D2
D0/D1 1.923 1.525–2.424 <0.001 2.361 1.771–3.147 <0.001
Neo-adjuvant chemotherapy
Yes
No 1.260 0.756–2.100 0.374 NA NA NA
Adjuvant chemotherapy
No
Yes 0.978 0.710–1.347 0.892 NA NA NA
Adjuvant chemotherapy regimen
No
Fluorouracil-based regimens 0.947 0.687–1.306 0.740 NA NA NA
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increased risk of peritoneum implanting. Receiving adju-
vant chemotherapy ≤3 cycles could improve the risk of
distant metastasis (OR 0.640, 95% CI 0.433 to 0.943).
Receiving adjuvant radiotherapy could reduce the risk of
distant metastasis (OR = 0.260, 95% CI 0.083 to 0.816),
and potential reduced the risk of local-regional recur-
rence (OR = 0.302, 95% CI 0.085 to 1.078).
The analysis for recurrence timing
During the follow-up, 793 patients experienced recur-
rence with the overall median RFS of 29.00 months
(IQR 12.07, 147.23). There were 554 patients suffering
early recurrence, with the median RFS of 10.77 months
(IQR 6.00, 15.83). Another 239 patients experienced late
recurrence, with the median DFS of 35.83 months (IQR
28.67, 50.67). Patients with T3–4 (OR = 2.148, 95% CI
1.537 to 3.001), N1–3 (OR = 1.874, 95% CI 1.320 to
2.660), and LN+%≧0.33(OR = 2.024, 95% CI 1.531 to
2.681) contributed to the higher early recurrence risk.
Having operation in general hospitals has potential to
suffer early recurrence (OR = 1.292, 95% CI 0.995 to
1.676). Having lymph nodes resection no less than 15
(OR = 0.625, 95% CI 0.480 to 0.815) could reduce the
risk of early recurrence.
Among the recurrence patients, the median RFS was
only 14.73 months (IQR 7.90, 26.17), and the median
RFS varied from recurrence types. The median RFS of
single local-regional recurrence, single distant metasta-
sis, single peritoneum implanting, and multiple patterns
recurrence was 19.47 months (IQR 10.40, 36.57),
13.67 months (IQR 6.90, 24.27), 14.17 months (IQR
7.73,25.33), and 14.33 months (IQR 7.80, 25.70), respect-
ively (Fig. 3a).
The survival outcome of each recurrence type
There were 668 patients dead during the follow-up, with
overall survival of 50.94 months (IQR 26.53, 205.73).
Among recurrent patients, the overall survival was as
short as 33.63 months (IQR 20.63, 54.87). The median
overall survival of single local-regional recurrence, single
distant metastasis, single peritoneum implanting, and
multiple patterns recurrence was 48.63 months (IQR
24.17, 122.40), 35.70 months (IQR 24.00, 57.80),
29.50 months (IQR 17.90,45.77), and 28.03 months (IQR
18.10, 47.37), respectively (Fig. 3b).
Discussion
Most studies had noted that curative resection for gastric
cancer focused largely on prognosis [15, 16]. In China,
most recurrence pattern data was based on small sample,
single-center database [10–12], which could not actually
reflect the presence of gastric cancer treatment. And little
studies noted recurrence timing and took the surgical hos-
pitals’ influence on recurrence into consideration. This
study was important, because it firstly aimed to identify
the incidence, patterns, and timing of recurrence after
curative resection for gastric cancer in a large sample and
multiple-center cohort of Chinese patients. The outcomes
not only provided Chinese presence of curative resection
for gastric cancer but also informed the points, which
clinicians should focus during the postoperative follow-up.
As this analysis noted, 60.8% patients experienced
recurrence after curative resection for gastric cancer,
which was similar with previous results [10, 12, 15]. The
incidence of distant metastasis was comparably high
(30–45%) all over the world [3, 5, 7, 8, 10–12, 17, 18].
Patients in Japan and South Korea suffered lower local-
regional recurrence compared with China (7-10 vs.
32.4%) [7–9]. But American patients suffered higher
local-regional recurrence in contrast with the Chinese
(44.1 vs. 32.4%) [3]. However, peritoneum implanting in
China was obviously lower than in Japan, South Korea,
and USA (13.7 vs. 30–45.9%) [3, 7, 8, 18, 19]. It might
associate with less sensitive imaging examination (even
MRI/CT with only 56% sensitivity for peritoneum
implanting) [20], less laparoscopic exploration, and
cytological examination of peritoneal lavage fluid. The
actual incidence of peritoneum implanting would be
higher in China.
Based on this analysis, the difference between surgical
hospitals and recurrence was specifically analyzed.
Receiving operation in general hospitals contributed to
higher recurrence risk and shorter RFS (Fig. 3c, p < 0.001).
It partly related less lymph nodes harvest and lower D2
Table 2 The univariate and multivariate analysis of postoperative recurrence (Continued)
Other regimens 2.414 1.096-5.315 0.029 NA NA NA
Adjuvant chemotherapy cycles
No
≦3 cycles 0.754 0.527–1.080 0.123 NA NA NA
>3 cycles 1.156 0.827–1.617 0.396 NA NA NA
Adjuvant radiotherapy
Yes
No 2.152 0.980–4.725 0.056 3.868 1.493–10.022 0.005
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Table 3 The univariate and multivariate analyses of each recurrence pattern
Local-regional recurrence Distant metastasis Peritoneum implanting
Clinical features Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
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lymphadenectomy ratio in general hospital. Although the
time span of this study was as long as 27 years and D2
lymphadenectomy was just generalized in the past
15 years, specialist hospitals had higher lymph nodes
harvest ≧15 rate D2 lymphadenectomy rate at every
period (from Jan. 1986 to Dec. 1999, 40.7 and 34.0% vs.
19.5 and 13.3%; from Jan. 2000 to Dec. 2006, 69.0 and
58.1% vs. 33.2 and 29.9%; from Jan. 2007 to Sept. 2013,
77.3 and 73.6% vs. 59.1 and 57.4%). It might relate to less
volume of curative gastric cancer resection in general hos-
pitals [21] and earlier D2 lymphadenectomy generalization
in specialist hospitals. It also referred that standard D2
lymphadenectomy training of clinicians should be contin-
ued in China. And increased T stage was the most import-
ant independently risk factor of recurrence and with
worse RFS (Fig. 3d, p < 0.001). Several studies had noted
that postoperative recurrence associated with factors, such
as T stage, extent of lymph node invasion, and tumor loca-
tion [3, 7, 10–12, 17, 19, 22–26], which were consistent
with this study. Based on this database, female and signet
ring cell cancer contributed to increased incidence of peri-
toneum implanting, which reported in previous results
[17, 27]. However, we did not find that lymph node inva-
sion related to peritoneum implanting [22]. The age of pa-
tients closely associated with distant metastasis and
peritoneum implanting. Patients older than 65 years old
had higher risk of distant metastasis and lower risk of
peritoneum implanting. In further study, in the group of
patients older than 65 years old, less patients were signet
ring cell cancer (5.9 vs. 13.0%, p < 0.001) and more
patients did not receive adjuvant chemotherapy (22.6 vs.
12.9%, p < 0.001), comparing with the group of patients no
more than 65 years old. It might explain the results. In
addition, among patients with signet ring cell cancer,
compared with subtotal gastrectomy, patients with
total gastrectomy contribute to slightly lower risk of
peritoneum implanting (10.0 vs. 15.2%) and multiple
patterns recurrence (23.3 vs. 33.0%). It might be bet-
ter to underwent total gastrectomy for signet ring cell
cancer patients.
The overall median RFS noting in this analysis was
29.00 months, which was similar to the results in USA [3].
Of note was the further study that the median RFS among
patients with recurrence was much shorter, at a little more
than 1 year (14.73 months), as the previous study reported
[17, 19]. Single local-regional recurrence occurred later
than any other recurrence types and had better overall
survival. The overall 3- and 5-year survival rates were
63.8 and 44.8%, respectively, which were higher than
Fig. 3 a The survival curves for RFS of different recurrence patterns.
b The survival curves for OS of different recurrence patterns. c The
survival curves for RFS of different surgical hospitals. d The survival
curves for RFS of different T status
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previous American study (50.9 and 39.3%) [3]. In fur-
ther study, the median survival after recurrence was
only 13.97 months (IQR 7.03, 24.67), which was con-
sistent with the results of Koizumi W and colleague
(13.0 months) [28]. And early recurrence patients had
worse survival after recurrence than late recurrence
patients (13.50 vs. 16.30 months, p = 0.023), which did
not show in American analysis [3].
In this study, Chinese patients had more multiple
pattern recurrence than patients in America and South
Korea (42.5 vs. 33.2 vs. 16.3–27.4%) [3, 19, 29]. It partly
reflected the lack of regular postoperative follow-up in
China. A large part of recurrence was early recurrence
and 5-year DFS was only 5.2%. So, that receiving operative
examination every 3 months within 2 years and every
6 months within 5 years after surgery were recommended
[30, 31], especially for patients with such risk factors.
There were also several limitations in this study. At
first, as the patients undergoing surgery in more than
100 hospitals in China, selection bias was unavoidable.
Nevertheless, in China, it was general for patients receiv-
ing radical resection and adjuvant treatment in different
hospitals. Secondly, several other factors previously
reported as associated with the recurrence, such as
tumor size, vascular tumor thrombus, and Lauren classi-
fication did not include this study. Thirdly, the relation-
ship of D2 lymphadenectomy and lymph nodes harvest
≧15 to recurrence were different, which associated with
long time span of surgery and loss of detail surgical
records. And then, in this study, we only found had no
more than 3 cycles of adjuvant chemotherapy could
reduce the recurrence, with statistical significance. More
cycles of adjuvant chemotherapy also potential to reduce
recurrence. It might associate with different chemother-
apy regimens and bias in retrospective study. However,
we could not find the association between neo-adjuvant
chemotherapy, adjuvant chemotherapy regimens, and
recurrence. And although we found that adjuvant radio-
therapy could reduce postoperative recurrence and dis-
tant metastasis, the results were lower reliability because
of small samples. Last but not the least, some patients
were lost during follow-up, without information on
recurrence or death. All these issues might have led to
potential bias in the analysis of recurrence patterns and
timing after curative gastric cancer resection.
Conclusions
In brief, this multiple-center retrospective analysis noted
that postoperative recurrence of gastric cancer was com-
mon, especially early recurrence. Advanced tumor stage
and large tumor burden contributed to increased recur-
rence risk and worse survival. Enough lymph nodes har-
vest and standard D2 lymphadenectomy could reduce the
postoperative recurrence. Patients might benefit from
adjuvant chemotherapy and radiotherapy in China.
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